Micardis, Telmisartan News

Objective: To examine the long-term renal effects of telmisartan versus placebo in adults at high vascular risk.

The summary below is from the full report titled "Effect of Telmisartan on Renal Outcomes.

Results of the HIGHCARE2008 Project were announced during the recent 19th Scientific Meeting of the European Society of Hypertension , Milan, Italy.

Data presented today at the 19th Scientific Meeting of the European Society of Hypertension, Milan, Italy has demonstrated that treatment with an investigational combination of telmisartan and amlodipine shows substantial and sustained 24-hour blood pressure lowering and is well-tolerated in a range of patients with hypertension at risk of ...

From the University of Glasgow, Faculty of Medicine, Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow, UK.

Correspondence to Magdy Selim, MD, PhD, Beth Israel Deaconess Medical Center - Stroke Division, 330 Brookline Avenue, Palmer 127, Boston, MA 02215.

Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. announced today that on 22 April the approval of manufacture and marketing of MicombiCombination Tablets was obtained.

Managing diabetes in patients with concomitant disorders: Obesity Metabolic syndrome Cardiovascular disease Chronic kidney disease Hypertension Diabetes in different patient populations: Blacks Hispanics DPP-4 inhibitors and investigational drugs Clinical trial findings Diabetes in active patients and athletes Submission deadline: : March.

Hypertension. 2009 Published online before print March 16, 2009, doi: 10.1161/HYPERTENSIONAHA.108.126656 Submitted on November 17, 2008 Revised on November 24, 2008 Inhibition of Tumor Necrosis Factor- -Induced ...

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

METHODS: We included 78 patients . After a 4-week wash-out period, patients were randomly assigned to telmisartan, 80 mg once daily or 80 mg twice daily , during a mean follow-up of 24.6 +/- 2.2 months.

To the Editor: We have eagerly awaited the results of the Prevention Regimen for Effectively Avoiding Second Strokes Study ,1 since a significant benefit of angiotensin-receptor blockers was anticipated based ...

CiteULike is a free online bibliography manager. Register and you can start organising your references online.